Table 1.
Summary of the approved ADCs and their common adverse events.
| Approved ADCs | Target | Indications | Approved Year/ R&D Organization |
Common Adverse Events (Any Grades) | Common Grade ≥ 3 Adverse Events |
|---|---|---|---|---|---|
| Gemtuzumab Ozogamicin (Mylotarg®) | CD-33 | Acute myeloid leukemia | 2001 Pfizer |
Thrombocytopenia, fatigue, neutropenia, pyrexia, nausea, infection, chills, hemorrhage, vomiting, headache, stomatitis, diarrhea, and abdominal pain | Neutropenia, thrombocytopenia, increased AST/ALT levels, and sepsis |
| Inotuzumab Ozogamicin (Besponsa®) | CD-22 | B-cell precursor acute lymphoblastic leukemia | 2017 Pfizer |
Neutropenia, thrombocytopenia, infection, anemia, leukopenia, febrile neutropenia, and nausea | Neutropenia, thrombocytopenia, leukopenia, febrile neutropenia, anemia, and lymphopenia |
| Brentuximab Vedotin (Adcetris®) | CD-30 | Hodgkin lymphoma, systemic anaplastic large-cell lymphoma, T-cell lymphoma | 2011 Seattle Genetics |
Peripheral sensory neuropathy, nausea, fatigue, neutropenia, diarrhea, pyrexia, vomiting, arthralgia, pruritus, myalgia, peripheral motor neuropathy, and alopecia | Neutropenia, peripheral sensory neuropathy, thrombocytopenia, and anemia |
| Polatuzumab Vedotin (Polivy®) | CD-79b | Diffuse large B-cell lymphoma | 2019 Genentech |
Neutropenia, anemia, and peripheral neuropathy | Neutropenia, anemia, and peripheral sensory neuropathy |
| Enfortumab Vedotin (Padcev®) | Nectin-4 | Urothelial cancer | 2019 Astellas |
Fatigue, alopecia, decreased appetite, dysgeusia, nausea, peripheral sensory neuropathy, pruritus, diarrhea, and maculopapular rash | Rash, neutropenia, anemia, and fatigue |
| Tisotumab Vedotin (Tivdak®) | Tissue factor | Cervical cancer | 2021 Genmab |
Epistaxis, fatigue, nausea, alopecia, conjunctivitis, decreased appetite, constipation, diarrhea, vomiting, peripheral neuropathy, dry eye, and abdominal pain | Fatigue, anemia, abdominal pain, hypokalemia, conjunctivitis, hyponatremia, peripheral neuropathy, and vomiting |
| Belantamab Mafodotin (Blenrep®) | B-cell maturation antigen | Multiple myeloma | 2020 GSK |
Keratopathy, thrombocytopenia, anemia, nausea, pyrexia, blurred vision, increased aspartate aminotransferase | Keratopathy, thrombocytopenia, anemia |
| Trastuzumab Emtansine (Kadcyla®) | HER-2 | Breast cancer | 2013 Genentech |
Thrombocytopenia, elevated transaminases, fatigue, anemia, and nausea | Thrombocytopenia, increased aspartate aminotransferase levels, and anemia |
| Mirvetuximab Soravtansine (Elahere®) | Folate receptor α | Ovarian cancer | 2022 Immunogen |
Nausea, blurred vision, keratopathy, diarrhea, fatigue, peripheral neuropathy, dry eye, and decreased visual acuity | Blurred vision, peripheral neuropathy, and diarrhea |
| Trastuzumab Deruxtecan (Enhertu®) | HER-2 | Breast cancer | 2019 Daiichi Sankyo |
Nausea, fatigue, alopecia, vomiting, neutropenia, constipation, anemia, decreased appetite, diarrhea, leukopenia, and thrombocytopenia | Neutropenia, anemia, nausea, leukopenia, lymphopenia, and fatigue |
| Sacituzumab Govitecan (Trodelvy®) | Trop-2 | Breast cancer, urothelial cancer | 2020 Gilead Sciences |
Nausea, diarrhea, neutropenia, fatigue, vomiting, anemia, alopecia, and constipation | Neutropenia, anemia, diarrhea, and leukopenia |
| Loncastuximab Tesirine (Zynlonta®) | CD-19 | Large B-cell lymphoma | 2021 ADC Therapeutics |
Neutropenia, thrombocytopenia, anemia, fatigue, and gamma-glutamyl transferase increase | Thrombocytopenia, neutropenia, anemia, gamma-glutamyl transferase increased, leukopenia, lymphopenia, and hypophosphatemia |